Good morning, everyone, and welcome to the last day of the 2026 J.P. Morgan Healthcare Conference. My name is Ben Davis. I’m an associate with the Healthcare Investment Banking team at JPMorgan. And I’m pleased to introduce Richard Adcock, CEO; and David Sachs, CFO of ImmunityBio. Richard will be running through his presentation, after which we’ll have some time for questions and answers.
Thank you. Thanks for everybody being here, and thanks, [ Benjamin ] and JPMorgan team for inviting us. Today, what I really want to do is talk to you about what did we do in 2025, setting us up for 2026. I think the most important thing to note is that we had an absolutely incredible 2025. And if you’ve been following the press releases that we’ve been issuing this week, really spotlight a number of pieces, and I’ll be talking about those in more detail.
Everyone here is familiar with forward-looking statements. So in 2025, and I’m not going to read every word on the slide here, we really are going to provide you an update on what do we do in bladder, what are we doing in lung, lymphopenia and then other solid tumors like pancreatic and you’ll see some others as well on these. In bladder cancer, obviously, as everyone knows, we got our approval in 2024. But right out of the gate, we said that we’re going to need the reimbursement code.
So January of this year was when we received our J-Code, and that’s really when the commercial team really was able to
